Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development that informs Chemically Reactive Metabolite formation

ABSTRACT: Transcriptional responses in rat liver following treatment with compounds with a range of in vitro covalent binding measurements

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE149734 | GEO | 2020/06/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development That Informs Chemically Reactive Metabolite Formation and Potential for Drug-induced Liver Injury.

Project description: Not available

| S-EPMC7553701 | biostudies-literature

Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development that informs Chemically Reactive Metabolite formation

Project description:Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development that informs Chemically Reactive Metabolite formation

| PRJNA629815 | ENA

Reactive Metabolite-induced Protein Glutathionylation Mechanistically Accounts for Acetaminophen Hepatotoxicity

Project description:Although covalent protein binding is established as the pivotal event underpinning acetaminophen (APAP) toxicity, its mechanistic details remain unclear. In this study, we demonstrated that APAP induces widespread protein glutathionylation in a time-, dose- and bioactivation-dependent manner in HepaRG cells. Proteo-metabonomic mapping provided evidence that APAP-induced glutathionylation resulted in functional deficits in energy metabolism, elevations in oxidative stress and cytosolic calcium, as well as mitochondrial dysfunction that correlate strongly with the well-established toxicity features of APAP. We also provide novel evidence that APAP-induced glutathionylation of carnitine O-palmitoyltransferase 1 (CPT1) and voltage-dependent anion-selective channel protein 1 are respectively involved in inhibition of fatty acid β-oxidation and opening of the mitochondrial permeability transition pore. Importantly, we show that the inhibitory effect of CPT1 glutathionylation can be mitigated by PPARα induction, which provides a mechanistic explanation for the prophylactic effect of fibrates, which are PPARα ligands, against APAP toxicity. Finally, we suggest that APAP-induced protein glutathionylation likely occurs secondary to covalent binding, which is a previously unknown mechanism of glutathionylation, demonstrating that this post-translational modification is functionally implicated in drug-induced toxicity.

2018-09-20 | PXD009986 | JPOST Repository

Application of folding stability-based proteomics to profile cancer drug

Project description:Covalent inhibitors offer powerful therapeutic advantages but require comprehensive profiling to define their on- and off-target activities. Here, we apply two stability-based proteomic methods, SPROX and TPP, to characterize protein targets of the KRASG12C inhibitor ARS-1620 in H358 cell lysate. Both methods identified ligand-induced protein stability shifts, collectively recovering the known on-target KRAS as well as multiple off-targets. Comparative analyses with ABPP and pull-down datasets highlighted ALDH1A3 as a reproducible off-target. Bottom-up proteomics mapped Cys314 as the major ARS-1620 modification site on ALDH1A3, and enzymatic assays confirmed dose-dependent inhibition. Covalent docking supported a favorable binding pose within the retinal-binding pocket. Together, these findings demonstrate that stability-based proteomics provides an effective, derivatization-free strategy for covalent drug target identification.

2026-05-08 | PXD070862 | Pride

Hepatic Bioactivation of Skin-Sensitizing Drugs to Immunogenic Reactive Metabolites.

Project description: Not available

| S-EPMC6714514 | biostudies-literature

Sapitinib: reactive intermediates and bioactivation pathways characterized by LC-MS/MS.

Project description: Not available

| S-EPMC9073192 | biostudies-literature

Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.

Project description: Not available

| S-EPMC6891204 | biostudies-literature

TOP1cc-seq assay in human cancer cells

Project description:TOP1cc-seq assay was performed for the quantitative detection of the transient DNA-protein covalent interactions upon acute stimulations.

2022-08-04 | GSE135723 | GEO

Expanding the repertoire of chemically induced covalent neoantigens

Project description:The ubiquitin-proteasome system (UPS) generates peptide fragments that are displayed on class I major histocompatibility complex (MHC-I) molecules. Hapten-modified peptides, which are derived from proteins covalently modified by exogenous small molecules, have long been proposed as a mechanism for immune recognition. Building on this concept, recent studies have begun to harness this mechanism for therapeutic purposes, demonstrating that covalent small molecules can engage this pathway to drive the presentation of hapten-modified peptide fragments, or covalent neoantigens. Here, we report a platform to systematically investigate this process and harness covalent neoantigens for immune cell recruitment and activation. Using bioorthogonal cysteine-reactive probes, we demonstrate that covalently modified intracellular proteins can be processed and presented as covalent neoantigens in multiple cell lines. Immunopeptidomics confirmed the presence of probe-modified peptides within the MHC-I immunopeptidome. We further integrated a bioorthogonal strategy for immune cell engagement by pairing methyltetrazine (mTz)-tagged covalent neoantigens with trans-cyclooctene (TCO)-conjugated immune cell recruiters, leading to the activation of CD32- and CD3-expressing reporter immune cells. These findings indicate an expanded scope of covalent neoantigen formation and provide a generalizable strategy for immune targeting of covalent neoantigens.

2026-07-08 | PXD077352 | Pride

Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite N-desethylamodiaquine.

Project description: Not available

| S-EPMC5306493 | biostudies-literature